Pharmacokinetics and pharmacodynamics of newer fluoroquinolones

Clinical Infectious Diseases

Volumn 23, Issue SUPPL. 1, 1996, Pages

  Stein, Gary E ^a,b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CLINAFLOXACIN; CYCLOSPORIN; ENOXACIN; FELBINAC; FENBUFEN; GREPAFLOXACIN; LEVOFLOXACIN; NONSTEROID ANTIINFLAMMATORY AGENT; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SITAFLOXACIN; SPARFLOXACIN; THEOPHYLLINE; TROVAFLOXACIN; WARFARIN;

ANAEROBIC INFECTION; ANIMAL MODEL; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; BACTEROIDES FRAGILIS; DRUG ABSORPTION; DRUG METABOLISM; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 0029807785     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/23.supplement_1.s19     Document Type: Article

References (10)

1. Domagala JM. Structure-activity and structure-side-effect relationships for the quinolone antibacterials. J Antimicrob Chemother 1994;33:685-706.
2. Wolfson JS, Hooper DC. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev 1989; 2:378-424.
3. Richard P, Gutmann L. Sparfloxacin and other new fluoroquinolones. J Antimicrob Chemother 1992;30:739-44.
4. Montay G, Bruno R, Vergniol JC, et al. Pharmacokinetics of sparfloxacin in humans after single oral administration at doses of 200, 400, 600 and 800 mg. J Clin Pharmacol 1994;34:1071-6.
5. Davis R, Bryson HM. Levofloxacin: a review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 1994;47:677-700.
6. Uematsu T, Nagashma T, Takiguchi Y, Nakashima M. OPC-17116, a new quinolone: phase I study [abstract 1481]. In: Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 1991.
7. Wise R, Mortiboy D, Child J, Andrews JM. Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219). Antimicrob Agents Chemother 1996;40:47-9.
8. Investigators brochure: Clinafloxacin (CI-960). Ann Arbor, MI: Parke-Davis, August 1995.
9. Nakashima M, Uematsu T, Kosuge K, Umemura K, Hakusui H, Tanaka M. Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers. Antimicrob Agents Chemother 1995;39:170-4.
10. Thebault JJ, Montay G, Ebmeier M, et al. Effect of food on the bioavail-ability of the new quinolone RP-64206 [abstract 1249]. In: Program and abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy (Atlanta). Washington, DC: American Society for Microbiology, 1990.